Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis

Abstract

Cold urticaria is a subtype of chronic inducible urticaria (CIndU) associated with significant morbidity and a risk for anaphylaxis. Few studies have assessed the prevalence, management, and prevalence of associated anaphylaxis of cold urticaria. To evaluate the prevalence of cold urticaria among CIndU and chronic urticaria (CU) cases, to assess the management of cold urticaria, and to determine the prevalence of associated anaphylaxis. We searched PubMed and EMBASE for studiespertaining to cold urticaria and/or CIndU published in the past 10 years. We conducted meta-analyses to evaluate theprevalence of cold urticaria among CIndU and CU cases,the management of cold urticaria with H1-antihistamines andomalizumab, and the prevalence of associated anaphylaxis. Twenty-two studies were included in the systematicreview and 14 in the meta-analysis. The pooled prevalence of cold urticaria among patients with CU and CIndU was 7.62% (95% confidence interval [CI], 3.45% to 15.99%; I2=98%) and 26.10% (95% CI, 14.17% to 43.05%; I2= 97%), respectively. Cold urticaria was managed by H1-antihistamines in 95.67% (95% CI, 92.47% to 97.54%; I2= 38%) of patients and omalizumab in 5.95% (95% CI , 2.55% to 13.27%; I2= 83%) of patients. The pooled prevalence of anaphylaxis among patientswith cold urticaria was 21.49% (95% CI, 15.79% to 28.54%; I2= 69%). Cold urticaria constitutes an appreciable proportion of CIndU and CU cases and is predominantly managed with H1-antihistamines; few patients receive omalizumab. Anaphylaxis is common, and an epinephrine autoinjector prescription may be considered.